Funded Biotechnology Startups in France
The 50 most recent funding rounds for French biotechnology companies span October 2025 back to May 2024, with disclosed amounts ranging from a $580K raise…
The 50 most recent funding rounds for French biotechnology companies span October 2025 back to May 2024, with disclosed amounts ranging from a $580K raise by GenSight Biologics to a $45M Series A by Genomines — both headquartered in Paris. Paris and the broader Ile-de-France region account for the largest share of activity, while Lyon's Rhone-Alpes cluster demonstrates consistent deal flow: MaaT Pharma ($44M), BrainEver ($39M Series B), ENYO Pharma (Series C), and at least five other Lyon-area companies all closed rounds since late 2024.
Series A is the most visible labeled stage, with nine companies raising between $5M and $45M. Over 30 rounds carry no stage designation, a pattern typical of European life sciences where public-company extensions and bridge financings often go unlabeled. Sub-sector diversity is notable: genomics platforms like SeqOne Genomics ($23M, Montpellier) and Coave Therapeutics ($33M Series A, Paris) sit alongside industrial biotech players such as Abolis Biotechnologies ($39M, Évry) and AFYREN ($5M, Rhone-Alpes), reflecting broad activity across therapeutic and non-therapeutic applications.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest recent funding rounds among French biotech companies in this dataset?
Genomines closed a $45M Series A in Paris in September 2025, followed by MaaT Pharma at $44M in Lyon (July 2025), BrainEver at $39M Series B (July 2025), and Abolis Biotechnologies at $39M in Évry (September 2024). TreeFrog Therapeutics ($34M, Bordeaux, May 2025) and Coave Therapeutics ($33M Series A, Paris, January 2025) round out the top six disclosed amounts.
Which cities and regions produce the most funded biotech companies in France?
Paris and the broader Ile-de-France region account for roughly 20 of the 50 companies, including Genomines, One Biosciences, Egle Therapeutics, EG 427, and Coave Therapeutics. Lyon's Rhone-Alpes cluster is the second most active hub, with at least 10 companies — among them MaaT Pharma, BrainEver, ENYO Pharma, Adocia, NETRI, and Allogenica — all raising since late 2024. Bordeaux/Aquitaine (TreeFrog Therapeutics, bYoRNA, inHEART) and Montpellier (SeqOne Genomics, Mabqi) represent meaningful secondary clusters.
How are round stages distributed across the 50 companies shown?
Nine rounds are labeled Series A, three are Series B, one is Series C (ENYO Pharma, Lyon), five are Seed, and one is Pre-Seed (bYoRNA, Bordeaux). Over 30 rounds carry no stage designation, a common pattern in European life sciences where listed companies and bridge financings frequently omit stage labels.
What is the typical Series A round size for French biotech companies here?
The nine Series A rounds in this dataset range from Genoskin's $5M (Toulouse, September 2025) to Genomines' $45M (Paris, September 2025). Excluding those two outliers, most cluster between $11M and $33M — EVerZom ($12M), inHEART ($11M), One Biosciences ($17M), Faircraft ($16M), Brenus Pharma ($25M), and Coave Therapeutics ($33M).
Which biotech sub-sectors appear most active in recent French funding rounds?
Genomics and gene therapy are well represented: Genomines, GenSight Biologics, Coave Therapeutics, Eligo Bioscience, and SeqOne Genomics all closed rounds within this window. Microbiome and gut-focused platforms appear through MaaT Pharma ($44M) and ENTEROME ($19M, Paris). Industrial and green biotech — AFYREN (biobased chemicals, Rhone-Alpes), Abolis Biotechnologies ($39M, Évry), and Overseed ($7M Series A, Orléans) — add a non-therapeutic dimension to the French deal flow.
Are there any very small or undisclosed rounds that suggest stealth or bridge activity?
Yes. GenSight Biologics raised only $580K in July 2025 and CTIBiotech closed $540K in June 2024, both in Lyon — amounts consistent with bridge or interim financing rather than primary raises. Three companies (NovAliX, Bon Vivant, Biobank) reported undisclosed amounts, and several "Series Unknown" rounds below $2M, such as Neovacs ($1M, May 2025), suggest similar extension or non-dilutive structures.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.